Gilead Sciences beat earnings expectations in Q2 2025, raised full-year guidance, and declared a dividend, despite insider sales and a stock dip.

In Q2 2025, Gilead Sciences reported strong earnings with $2.47 EPS and $7.77 billion in revenue, exceeding expectations, and raised its 2025 full-year guidance to $8.05–8.25 per share. The company announced a quarterly dividend of $0.79, yielding 2.5%, and saw insider sales totaling 115,146 shares worth $14 million, including sales by CEO Daniel Patrick O’Day and Johanna Mercier. Institutional investors reduced stakes, with Scotia Capital, Schroder, and Level Four Advisory Services trimming holdings. Despite a 11.2% stock decline during the quarter, Gilead’s shares traded at $125.85, with a market cap of $156.13 billion and a consensus “Moderate Buy” rating.